IDEAYA Biosciences (NASDAQ:IDYA) Earns Outperform Rating from Wedbush

IDEAYA Biosciences (NASDAQ:IDYA)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research report issued on Tuesday,Benzinga reports. They presently have a $52.00 price objective on the stock. Wedbush’s price target points to a potential upside of 99.62% from the company’s previous close.

A number of other equities research analysts have also weighed in on IDYA. Stephens began coverage on shares of IDEAYA Biosciences in a report on Monday, November 18th. They set an “overweight” rating and a $51.00 price target for the company. Cantor Fitzgerald began coverage on shares of IDEAYA Biosciences in a report on Tuesday, October 15th. They set an “overweight” rating for the company. Citigroup decreased their price objective on shares of IDEAYA Biosciences from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday, August 27th. Leerink Partners lowered shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Finally, Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $53.67.

IDEAYA Biosciences Trading Up 3.4 %

IDYA opened at $26.05 on Tuesday. The company has a fifty day simple moving average of $28.66 and a 200 day simple moving average of $34.30. The firm has a market cap of $2.25 billion, a price-to-earnings ratio of -11.18 and a beta of 0.79. IDEAYA Biosciences has a twelve month low of $24.72 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter last year, the business earned ($0.46) EPS. On average, analysts forecast that IDEAYA Biosciences will post -2.45 earnings per share for the current fiscal year.

Institutional Trading of IDEAYA Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. KBC Group NV increased its position in IDEAYA Biosciences by 29.1% during the third quarter. KBC Group NV now owns 2,274 shares of the company’s stock worth $72,000 after acquiring an additional 513 shares during the period. Amalgamated Bank lifted its position in IDEAYA Biosciences by 22.9% during the 3rd quarter. Amalgamated Bank now owns 2,840 shares of the company’s stock worth $90,000 after buying an additional 530 shares in the last quarter. US Bancorp DE lifted its position in IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company’s stock worth $54,000 after buying an additional 689 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of IDEAYA Biosciences by 35.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,056 shares of the company’s stock valued at $94,000 after purchasing an additional 796 shares during the last quarter. Finally, Allworth Financial LP raised its position in shares of IDEAYA Biosciences by 800.0% in the 3rd quarter. Allworth Financial LP now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 800 shares during the period. 98.29% of the stock is currently owned by institutional investors and hedge funds.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.